Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas

Abstract While prolactinoma patients have high bone turnover, current data are inconclusive when it comes to determining whether correction of hyperprolactinemia and associated hypogandism improves osteodensitometric data in men and women over the long term. In a large cohort of including 40 men and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lukas Andereggen, Janine Frey, Robert H. Andres, Markus M. Luedi, Hans Rudolf Widmer, Jürgen Beck, Luigi Mariani, Emanuel Christ
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/93fdd5fb480347169e2e77e8f9dc9ad9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:93fdd5fb480347169e2e77e8f9dc9ad9
record_format	dspace
spelling	oai:doaj.org-article:93fdd5fb480347169e2e77e8f9dc9ad92021-12-02T13:20:12ZPersistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas10.1038/s41598-021-84606-x2045-2322https://doaj.org/article/93fdd5fb480347169e2e77e8f9dc9ad92021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-84606-xhttps://doaj.org/toc/2045-2322Abstract While prolactinoma patients have high bone turnover, current data are inconclusive when it comes to determining whether correction of hyperprolactinemia and associated hypogandism improves osteodensitometric data in men and women over the long term. In a large cohort of including 40 men and 60 women, we studied the long-term impact of prolactinoma treatment on bone mineral density (BMD) in men versus women, assessed adverse effects of a primary surgical or medical approach, and evaluated data for risk factors for impaired BMD at last follow-up using multivariate regression analyses. Median duration of follow-up was 79 months (range 13–408 months). Our data indicate that the prevalence of impaired BMD remained significantly higher in men (37%) than in women (7%, p < 0.001), despite the fact that hyperprolactinemia and hypogonadism are under control in the majority of men. We found that persistent hyperprolactinemia and male sex were independent risk factors for long-term bone impairment. Currently, osteoporosis prevention and treatment focus primarily on women, yet special attention to bone loss in men with prolactinomas is advised. Bone impairment as “end organ” reflects the full range of the disease and could become a surrogate marker for the severity of long-lasting hyperprolactinemia and associated hypogonadism.Lukas AndereggenJanine FreyRobert H. AndresMarkus M. LuediHans Rudolf WidmerJürgen BeckLuigi MarianiEmanuel ChristNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Lukas Andereggen Janine Frey Robert H. Andres Markus M. Luedi Hans Rudolf Widmer Jürgen Beck Luigi Mariani Emanuel Christ Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas
description	Abstract While prolactinoma patients have high bone turnover, current data are inconclusive when it comes to determining whether correction of hyperprolactinemia and associated hypogandism improves osteodensitometric data in men and women over the long term. In a large cohort of including 40 men and 60 women, we studied the long-term impact of prolactinoma treatment on bone mineral density (BMD) in men versus women, assessed adverse effects of a primary surgical or medical approach, and evaluated data for risk factors for impaired BMD at last follow-up using multivariate regression analyses. Median duration of follow-up was 79 months (range 13–408 months). Our data indicate that the prevalence of impaired BMD remained significantly higher in men (37%) than in women (7%, p < 0.001), despite the fact that hyperprolactinemia and hypogonadism are under control in the majority of men. We found that persistent hyperprolactinemia and male sex were independent risk factors for long-term bone impairment. Currently, osteoporosis prevention and treatment focus primarily on women, yet special attention to bone loss in men with prolactinomas is advised. Bone impairment as “end organ” reflects the full range of the disease and could become a surrogate marker for the severity of long-lasting hyperprolactinemia and associated hypogonadism.
format	article
author	Lukas Andereggen Janine Frey Robert H. Andres Markus M. Luedi Hans Rudolf Widmer Jürgen Beck Luigi Mariani Emanuel Christ
author_facet	Lukas Andereggen Janine Frey Robert H. Andres Markus M. Luedi Hans Rudolf Widmer Jürgen Beck Luigi Mariani Emanuel Christ
author_sort	Lukas Andereggen
title	Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas
title_short	Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas
title_full	Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas
title_fullStr	Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas
title_full_unstemmed	Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas
title_sort	persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/93fdd5fb480347169e2e77e8f9dc9ad9
work_keys_str_mv	AT lukasandereggen persistentboneimpairmentdespitelongtermcontrolofhyperprolactinemiaandhypogonadisminmenandwomenwithprolactinomas AT janinefrey persistentboneimpairmentdespitelongtermcontrolofhyperprolactinemiaandhypogonadisminmenandwomenwithprolactinomas AT roberthandres persistentboneimpairmentdespitelongtermcontrolofhyperprolactinemiaandhypogonadisminmenandwomenwithprolactinomas AT markusmluedi persistentboneimpairmentdespitelongtermcontrolofhyperprolactinemiaandhypogonadisminmenandwomenwithprolactinomas AT hansrudolfwidmer persistentboneimpairmentdespitelongtermcontrolofhyperprolactinemiaandhypogonadisminmenandwomenwithprolactinomas AT jurgenbeck persistentboneimpairmentdespitelongtermcontrolofhyperprolactinemiaandhypogonadisminmenandwomenwithprolactinomas AT luigimariani persistentboneimpairmentdespitelongtermcontrolofhyperprolactinemiaandhypogonadisminmenandwomenwithprolactinomas AT emanuelchrist persistentboneimpairmentdespitelongtermcontrolofhyperprolactinemiaandhypogonadisminmenandwomenwithprolactinomas
_version_	1718393225016770560

Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas

Ejemplares similares